Staphylococcus aureus infective endocarditis (SAIE) is a complication of S. aureus bacteremia in 4 clinically distinct groups: injection drug users, hospitalized patients with nosocomial infections, prosthetic valve recipients, Table 1 
. Main characteristics of the 7 endocarditis databases that have included data for cases of definite infective endocarditis (IE).

Characteristic
Site of database Philadelphia, PA [14] Durham, NC [15] Besanç on, France [16] Marseille, France [17] London, England [18] Goteborg, Sweden [19] Barcelona, Spain [20] All sites combined Study period 1988-1990 1995-1999 1990-1999 1988-1999 1979-1999 1995-1999 1979-1999 1979-1999 Cases of IE single-site enrollment, and/or inclusion of a wide spectrum of clinical factors influencing patient outcome. As a result of these limitations, fundamental features of S. aureus native valve infective endocarditis (SA-NVIE) remain unclear. The International Collaboration on Endocarditis Merged Database (ICE-MD) was designed to provide a large, multicenter, international resource for data on uniformly defined cases of infective endocarditis. The objective of the ICE-MD project is to evaluate regional and global aspects of infective endocarditis and to improve understanding of the clinical characteristics and outcome of a large, international cohort of patients with well-characterized infective endocarditis [13] . In this report, we defined risk factors, clinical characteristics, and prognostic factors for adverse outcomes among patients with definite SA-NVIE.
PATIENTS, MATERIALS, AND METHODS
Patient data. The methods used to create the ICE-MD have been described elsewhere [12] [13] [14] . In brief, the International Collaboration on Endocarditis investigators were queried to determine sites that maintained prospective databases in an electronic format. The ICE-MD was designed to allow a multinational consortium of investigators to have the ability to combine existing databases, with data collected during 1979-1999 about prospectively identified patients with infective endocarditis. Seven sites from 5 countries (United States [15, 16] , France [17, 18] , the United Kingdom [19] , Sweden [20] , and Spain [21] ) contributed data in a predesigned electronic format.
The database from each center was sent to the coordinating center (Duke Clinical Research Institute, Durham, NC) for characterization and merging. Key domains, which contained core variables common to the individual databases, were determined. Standard definitions for each core variable were developed, and the merger was accomplished with use of a hierarchial variable structure that was described previously [13] .
Definitions. Infective endocarditis was defined on the basis of the Duke Criteria [22] . Data entered into the merged databases that involved patients identified from 1979 to 1994 (i.e., before publication of the Duke criteria) were redefined retrospectively with use of this diagnostic schema. The variable "total embolism" included embolisms in any major arterial vessel, including pulmonary embolisms. CNS events were defined as CNS embolization, hemorrhage, or infection (e.g., meningitis or brain abscess). Surgical rates and mortality rates refer to inhospital surgery and mortality rates, respectively. The remaining clinical, echocardiographic, and outcome variables were defined as reported elsewhere [21] [22] [23] [24] .
Statistical analysis. Descriptive statistics for continuous variables were summarized as medians and interquartile ranges (IQRs). All sites did not collect all variables. Thus, each categorical variable was reported as the number of patients affected and as a percentage of patients for whom that variable was available. The Wilcoxon rank sum test and Fisher's exact test were used to evaluate group differences for continuous and categorical variables, respectively. Descriptive univariate analysis of mortality-related factors was performed. For univariate analysis, sites for which data were not available for the variable of interest were excluded. For the multivariable analysis, only those variables that were available from all sites were entered into the model. P values of !.05 were considered to be statistically significant. All analyses were performed using SAS software, versions 6.12 and 8.2 (SAS Institute).
RESULTS
Data for a total of 2212 cases from the 20-year study period were collected (table 1) . Native valve infective endocarditis (NVIE) was present in 81.2% of patients, and prosthetic valve infective endocarditis was present in 16.6%. Definite infective endocarditis due to S. aureus was present in 652 patients (29.5%), and SA-NVIE was present in 566 patients (25.6%). These 566 cases represent 353 cases in patients described in a previous report [14] , 209 cases associated with injection drug use, and 4 cases in patients aged !18 years.
Patients with SA-NVIE were younger and more likely to have comorbid conditions or to have engaged in injection drug use than were patients with non-SA-NVIE (table 2) . Patients with SA-NVIE were significantly less likely to have undergone valvular surgery (26.2% vs. 38.7%;
) and were more likely P ! .001 to die during hospitalization (19.9% vs. 12.2%; ) than P ! .001 were patients with non-SA-NVIE.
US patients with SA-NVIE were older, had a higher frequency of comorbid conditions, and had a lower rate of injection drug use than did European patients with SA-NVIE. Rates of periannular abscess formation, heart failure, and surgical therapy were similar between these 2 geographic regions.
Methicillin-resistant S. aureus (MRSA) endocarditis occurred in 14.8% of patients from centers where antimicrobial susceptibility testing was performed (table 3) . Mitral valve involvement predominated in patents with NVIE due to MRSA, and tricuspid infection predominated in patients with NVIE due to methicillin-susceptible S. aureus (MSSA). Rates of surgical therapy were similar among patients with NVIE due to MSSA and those with NVIE due to MRSA, although the mortality rate was higher for patients with NVIE due to MRSA (23.2% vs.
37.2%;
). P p .058 Right-side NVIE occurred in younger patients and in injection drug users, and it occurred less frequently during the last decade of the study (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (table 4) . Right-side NVIE was associated with fewer comorbid conditions (e.g., diabetes mellitus and chronic diseases) than was left-side NVIE. Surgical treatment was required more frequently for patients with leftside NVIE (39.7% vs. 12.4%;
), and the in-hospital P ! .001 mortality rate was also higher for patients with left-side NVIE (28.6% vs. 5.9%;
), compared with patients with right-P ! .001 side NVIE.
Univariate logistic regression analyses were used to quantify the relationship between important clinical characteristics and in-hospital mortality rates (table 5) . Important predictors of mortality in the study population included age (based on 10-year increments), presence of aortic or mitral valve vegetation, periannular abscess formation, heart failure, and CNS events. Characteristics associated with mortality in patients with SA-NVIE on multivariate analysis included increasing age (OR, 1.38; 95% CI, 1.15-1.66), presence of heart failure (OR, 3.90, 
DISCUSSION
Although S. aureus is an important cause of NVIE in the modern era, its relative infrequency at any single site has limited the ability to evaluate large cohorts of patients with this condition. In addition, the findings from such single-site reports may not be generalizable to other practice settings. The current investigation is a start in the attempt to overcome the limitations of previous SA-NVIE studies, because it uses a multinational collection of data for well-characterized patients, and it contributes to our understanding of this disease with several key observations. The current investigation is, to our knowledge, the first to provide compelling evidence underscoring a regional variation in the outcomes for patients with infective endocarditis. This regional variation persisted in a cohort of patients with the same disease type (NVIE) caused by the same pathogen (S. aureus), even after adjustment for a number of distinct patientspecific characteristics. Although such regional variation has been reported for other potentially lethal conditions, such as acute myocardial infarction [25] , it has not been previously identified for patients with infective endocarditis. The reasons for this finding may relate, in part, to regional variations in treatment strategies (e.g., different health care access, practice variations in antimicrobial therapy, and variations in referral patterns), in patient demographic characteristics (e.g., host susceptibility to S. aureus infection), or in innate virulence attributes of the pathogen. Of note, the current prospective International Collaboration on Endocarditis cohort study should begin to address the underlying causes of such regional variations [13] .
This investigation also emphasizes the increasing importance of S. aureus as a cause of NVIE in the modern era. In our cohort of 12000 patients with infective endocarditis, S. aureus was the most common cause of NVIE. By contrast, the proportion of cases of infective endocarditis due to viridans group streptococci or enterococci was significantly lower than that in studies that have encompassed cases from the last 2 decades [26, 27] . Our observations on the increasing prevalence of SA-NVIE reflect the probable convergence of 2 important trends: there is an increasing number of patients (e.g., geriatric patients and patients with transvenous pacemakers or indwelling catheters) who are at risk for endocarditis in general, and there is an increasing number of patients (e.g., patients with immunosuppression, diabetic patients, and persons undergoing hemodialysis) who are at risk for S. aureus bacteremia [8, 16, [28] [29] [30] . Given that gram-positive organisms have now overtaken gram-negative pathogens as the most common cause of septicemia in the United States [31] , it is likely that rates of SA-NVIE will continue to increase.
MRSA endocarditis occurred in 14.8% of patients from centers in which antimicrobial susceptibility testing was recorded, and at least one-third of SAIE cases were due to MRSA at one center since 1990. In agreement with prior observations [32, 33] , patients with NVIE due to MRSA tended to have more comorbid conditions than did patients with NVIE due to MSSA. The mortality rate for MRSA-infected patients also tended to be higher, although this observation did not achieve statistical significance ( ). Although some investiga-P p .054 tions have reported a similar association between MRSA infection and worse clinical outcomes [34] [35] [36] , others have failed to demonstrate this association when adjustment for comorbid conditions was made [30, 31, 37, 38] . It is still a matter of debate whether the increase in mortality for MRSA-infected patients is related to increased virulence of the strain, an increase in the number of comorbid diseases, or the relative ineffectiveness of vancomycin. Given the large increase in serious community-acquired MRSA infections in the past few years [39] , it is highly likely that the proportion of cases of SA-NVIE caused by MRSA will continue to increase.
The findings of the current investigation also confirm the virulence of S. aureus compared with other causes of NVIE. Patients with SA-NVIE in this and prior investigations [8, 10, 11, 28, 40, 41] had a higher mortality than patients with NVIE due to other pathogens. However, this is the first investigation to demonstrate this pathogen-specific virulence across different countries and health care systems. These findings suggest that S. aureus strains causing infective endocarditis possess a similar capacity for virulence throughout diverse geographic regions of the world.
The present study has several limitations. Different data collection methods were used at each site, potentially reducing the precision of certain core variables. Referral bias is also likely, because the study institutions are predominantly tertiary care referral centers. Finally, the apparent regional variation in outcome of SA-NVIE may be related to factors not specifically addressed in this investigation (e.g., varying rates of comorbid conditions, higher rates of injection drug use among individual sites, health care access, treatment practices, and potential virulence properties of bacteria). Thus, the findings of this investigation should be considered on for generation of hypotheses until they are externally validated with a separate cohort.
Despite these limitations, we believe that the findings of this study underscore the global significance of S. aureus and identify several patient and environmental factors associated with mortality in SA-NVIE. A large, prospective, multinational cohort study of patients with infective endocarditis is now under way to validate these observations and to further evaluate clinical, pathogen-specific, and host-specific determinants of outcome in this devastating infection.
SA-NVIE is a potentially life-threatening infection of global significance. It is primarily associated with either injection drug use or comorbid conditions. In this investigation, patients with SA-NVIE from different geographic regions had different risks of mortality. Future prospective, multinational investigations are required to validate our observations and to further evaluate clinical, pathogen-specific, and host-specific determinants of apparent differences in outcome between SA-NVIE and non-SA-NVIE. In the Results section of the abstract, the percentage listed after "566 patients" was incorrect and has been deleted. Also, the percentages of patients with S. aureus infective endocarditis who experienced embolic and central nervous system events should be 61% and 21%, respectively (not 60% and 20%, respectively). Finally, the 95% CI for periannular abscess should be 1.0-5.6 (not 1.1-5.6). The corrected section of the abstract appears below. The authors regret these errors. 95% CI, 1.0-5.6), heart failure (OR, 3.9; 95% CI, 2.3-6.7), and absence of surgical therapy (OR, 2.3; 95% CI, 1.3-4.2) as variables that were independently associated with mortality in patients with SA-NVIE. After adjusting for patient-, pathogen-, and treatment-specific characteristics by multivariate analysis, geographical region was also found to be associated with mortality in patients with SA-NVIE ( ). P ! .001
MEMBERS OF THE ICE
Results
For table 1, the references listed for the 7 databases are incorrect. The correct references are as follows: Philadelphia, PA [15] (not [14] ); Durham, NC [16] (not [15] ); Besançon, France [17] (not [16] ); Marseille, France [18] (not [17] ); London, England [19] (not [18] ); Goteborg, Sweden [20] (not [19] ); and Barcelona, Spain [21] (not [20] ). The journal and the authors regret these errors. Furthermore, the number of patients with native valve infective endocarditis for Durham, NC, should be 107 (not 10). The journal regrets this error. The corrected version of table 1 appears on the next page (p. 1076).
In addition, the authors would like to emend table 2. For the column labeled "Patients with non-SA-NVIE ( )," n p 1074 it should be noted that the data refer to cases that involve known pathogens. The corrected version of table 2 appears after table 1 (on p. 1077), with the added information shown in footnote a. Table 1 . Main characteristics of the 7 endocarditis databases that have included data for cases of definite infective endocarditis (IE).
Characteristic
Site of database Philadelphia, PA [15] Durham, NC [16] Besanç on, France [17] Marseille, France [18] London, England [19] Goteborg, Sweden [20] Barcelona, Spain [21] All sites combined NOTE. Data are no. (%) of patients, unless otherwise indicated. MRSA, methicillin-resistant S. aureus; NA, not available. a In-hospital mortality. b As a proportion of total cases of IE. c As a proportion of total cases of S. aureus IE, including both native valve MRSA IE (43 patients) and prosthetic valve MRSA IE (7 patients). d As a proportion of total cases of S. aureus IE.
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